DFX Intelligence
Private Credit Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
V••• H•••••• L••
Drug Discovery & Developmentgroup grade Aon a schedule nowsponsor unattributed
Also written as: 10; 10/31/2022; 11; 12; 12/11/2020; 2020; 2022; 31
Principal held
unknown
sum of BDC pieces, a lower bound
Fair value
$2.6M
n/a on cost, debt pieces
Unfunded
n/a
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
3 equity pieces beside them
Next maturity
unstated
no dated debt inside 24 months
On the tape since
Dec 31, 2022
latest Jun 30, 2026
Events
1
dated, non-routine
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Dec 31, 2023 | at least $4.8M | 100c | S+645 bp | May 1, 2024 | 1 |
Equity pieces beside the debt: preferred equity ($2.6M fair value, 1 BDC), warrants ($84,000 fair value, 1 BDC), other ($3.0M fair value, 1 BDC)
Lenders
every BDC piece at the latest quarter end
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | warrants equity Warrant, 6/15/2020, Common Units | n/a | $84,000 33c | |
| H••••••• C••••••• I••• | preferred equity equity Preferred Series C | n/a | $899,000 90c | |
| H••••••• C••••••• I••• | preferred equity equity Preferred Series B | n/a | $1.7M 55c |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1 | $0 | $0 | n/a | 0 |
| Mar 31, 2026 | 1 | $0 | $0 | n/a | 0 |
| Dec 31, 2025 | 1 | $0 | $0 | n/a | 0 |
| Sep 30, 2025 | 1 | $0 | $0 | n/a | 0 |
| Jun 30, 2025 | 1 | $0 | $0 | n/a | 0 |
| Mar 31, 2025 | 1 | $0 | $0 | n/a | 0 |
| Dec 31, 2024 | 1 | $0 | $0 | n/a | 0 |
| Sep 30, 2024 | 1 | $0 | $0 | n/a | 0 |
| Jun 30, 2024 | 1 | $0 | $0 | n/a | 0 |
| Mar 31, 2024 | 1 | $0 | $0 | n/a | 0 |
| Dec 31, 2023 | 1 | $4.8M | $5.6M | 100c | 0 |
| Sep 30, 2023 | 1 | $3.8M | $4.2M | 100c | 0 |
| Jun 30, 2023 | 1 | $5.3M | $5.6M | 100c | 0 |
| Mar 31, 2023 | 1 | $6.7M | $7.0M | 100c | 0 |
| Dec 31, 2022 | 1 | $8.1M | $8.4M | 100c | 0 |
What changed
- Facility left every BDC scheduleDec 31, 2023
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- VALO HEALTHderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it